BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $116.3 million versus the consensus estimate of $113.99 million.

GUIDANCE:

BioCryst Pharma sees FY2024 revenue of $443-448 million, versus the consensus of $436.3 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.